Valuation: Alumis Inc.

Market Cap 76Cr 67Cr 62Cr 56Cr 105.95Cr 7.16TCr 108.8Cr 741.44Cr 296.48Cr 3.79TCr 284.21Cr 278.11Cr 12TCr P/E 2026 *
-1.79x
P/E 2027 * -2.08x
Enterprise Value 4.12Cr 3.67Cr 3.36Cr 3.06Cr 5.76Cr 389.31Cr 5.92Cr 40Cr 16Cr 206.18Cr 15Cr 15Cr 650.6Cr EV / Sales 2026 *
6.58x
EV / Sales 2027 * 10x
Free-Float
96.45%
Yield 2026 *
-
Yield 2027 * -
1 day+1.62%
1 week-12.78%
Current month-12.78%
1 month-15.30%
3 months-78.88%
6 months-76.98%
Current year-39.86%
1 week 5.75
Extreme 5.75
6.81
1 month 5.75
Extreme 5.75
7.31
Current year 5.75
Extreme 5.75
31.35
1 year 4.4
Extreme 4.4
31.35
3 years 2.76
Extreme 2.7601
31.35
5 years 2.76
Extreme 2.7601
31.35
10 years 2.76
Extreme 2.7601
31.35
Manager TitleAgeSince
Chief Executive Officer 61 23/09/2021
Director of Finance/CFO 60 01/05/2022
Chief Tech/Sci/R&D Officer - 01/01/2022
Director TitleAgeSince
Director/Board Member 60 01/06/2021
Chairman 61 23/09/2021
Director/Board Member 55 01/05/2022
Date Insider Type Main position Quantity % Market Cap. Importance
08/09/26
Samsara BioCapital LLC
SellCompany -6,42,712 0.5207%
04/09/26 Other

Director

0 0%
03/08/26 Sell

Chief Technology Officer

-2,447 0.0020%
Change 5-day change 1-year change 3-year change Capi.($)
+1.20%-12.78%+24.36% - 76Cr
-4.83%+2.88%+55.87%+69.12% 6.94TCr
-1.18%-0.02%+9.44%+74.75% 5.72TCr
-1.65%+3.01%+24.83%+100.24% 5.76TCr
+2.01%+0.31%+27.17%+35.16% 4.37TCr
+5.13%+9.34%+21.83%+106.45% 4.4TCr
+3.39%-3.35%+201.24%+758.40% 3.81TCr
+7.50%+13.58%+29.07%+64.46% 3.63TCr
-4.11%-11.07%+86.29%+73.78% 3.26TCr
-2.18%+7.06%+36.06%-4.95% 2.55TCr
Average +0.60%+0.73%+51.62%+141.93% 4.05TCr
Weighted average by Cap. +0.11%+2.61%+50.51%+134.94%

Financials

2026 *2027 *
Net sales 62.61L 55.79L 51.03L 46.48L 87.61L 59Cr 89.97L 6.13Cr 2.45Cr 31Cr 2.35Cr 2.3Cr 99Cr 2.43Cr 2.17Cr 1.98Cr 1.81Cr 3.4Cr 229.97Cr 3.5Cr 24Cr 9.53Cr 121.79Cr 9.13Cr 8.94Cr 384.31Cr
Net income -43Cr -38Cr -35Cr -32Cr -60Cr -4.04TCr -61Cr -418.41Cr -167.31Cr -2.14TCr -160.39Cr -156.94Cr -6.75TCr -41Cr -36Cr -33Cr -30Cr -57Cr -3.86TCr -59Cr -400.15Cr -160.01Cr -2.05TCr -153.39Cr -150.09Cr -6.45TCr
Net Debt -72Cr -64Cr -58Cr -53Cr -100.18Cr -6.77TCr -102.88Cr -701.1Cr -280.35Cr -3.58TCr -268.75Cr -262.98Cr -11TCr -51Cr -46Cr -42Cr -38Cr -72Cr -4.86TCr -74Cr -503.2Cr -201.22Cr -2.57TCr -192.89Cr -188.75Cr -8.12TCr
Projected Income Statement - Annual - Alumis Inc.
Logo Alumis Inc.
Alumis Inc. is a late-stage biopharmaceutical company. The Company is engaged in developing next-generation targeted therapies with the potential to significantly improve patient health and outcomes across a range of immune-mediated diseases. Leveraging its proprietary data analytics platform and precision approach, the Company is developing a pipeline of oral tyrosine kinase 2 (TYK2) inhibitors, consisting of envudeucitinib for the treatment of systemic immune-mediated disorders, such as moderate-to-severe plaque psoriasis and systemic lupus erythematosus, and A-005 for the treatment of neuroinflammatory and neurodegenerative diseases. In addition, its pipeline also includes lonigutamab, a subcutaneously delivered anti-insulin-like growth factor 1 receptor therapy for the treatment of thyroid eye disease, as well as several preclinical programs identified through this precision approach.
Employees
238
Date Price Change Volume
06/26/06 $5.870 +0.34% 58,417
05/26/05 $5.850 -10.69% 19,50,463
04/26/04 $6.550 +0.77% 12,90,062
03/26/03 $6.500 +1.88% 25,66,618
02/26/02 $6.380 -5.20% 14,30,150
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
MarketScreener Ratings - Alumis Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
5.850USD
Average target price
31.12USD
Spread / Average Target
+432.05%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Alumis Inc.
  1. Stock Market
  2. Stocks
  3. ALMS Stock